Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-hydroxy atorvastatin** is a primary active metabolite of atorvastatin, a member of the statin class (HMG-CoA reductase inhibitors) used principally for lowering lipid levels and reducing cardiovascular risk. Like atorvastatin, this metabolite acts by competitively inhibiting the HMG-CoA reductase enzyme, thus reducing cholesterol biosynthesis in hepatocytes—including lower LDL-C and total cholesterol—as well as pleiotropic effects related to vascular protection. 2-hydroxy atorvastatin is formed in vivo by CYP3A metabolism of atorvastatin and is pharmacologically active, contributing significantly to the lipid-lowering effect seen with atorvastatin therapy. It has been investigated in vitro for neuroprotective effects and continues to be used primarily as a research compound rather than an approved drug for medical use[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-hydroxy atorvastatin.